SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Nasim M)
 

Sökning: WFRF:(Nasim M) > Selection of In Viv...

  • Mudie, Deanna M.Lonza, Global Res & Dev, Bend, OR 97703 USA (författare)

Selection of In Vivo Predictive Dissolution Media Using Drug Substance and Physiological Properties

  • Artikel/kapitelEngelska2020

Förlag, utgivningsår, omfång ...

  • 2020-01-27
  • SPRINGER,2020
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-407287
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-407287URI
  • https://doi.org/10.1208/s12248-020-0417-8DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • The rate and extent of drug dissolution in the gastrointestinal (GI) tract are highly dependent upon drug physicochemical properties and GI fluid properties. Biorelevant dissolution media (BDM), which aim to facilitate in vitro prediction of in vivo dissolution performance, have evolved with our understanding of GI physiology. However, BDM with a variety of properties and compositions are available, making the choice of dissolution medium challenging. In this tutorial, we describe a simple and quantitative methodology for selecting practical, yet physiologically relevant BDM representative of fasted humans for evaluating dissolution of immediate release formulations. Specifically, this methodology describes selection of pH, buffer species, and concentration and evaluates the importance of including bile salts and phospholipids in the BDM based upon drug substance log D, pK(a), and intrinsic solubility. The methodology is based upon a mechanistic understanding of how three main factors affect dissolution, including (1) drug ionization at gastrointestinal pH, (2) alteration of surface pH by charged drug species, and (3) drug solubilization in mixed lipidic aggregates comprising bile salts and phospholipids. Assessment of this methodology through testing and comparison with literature reports showed that the recommendations correctly identified when a biorelevant buffer capacity or the addition of bile salts and phospholipids to the medium would appreciably change the drug dissolution profile. This methodology can enable informed decisions about when a time, complexity, and/or cost-saving buffer is expected to lead to physiologically meaningful in vitro dissolution testing, versus when a more complex buffer would be required.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Samiei, NasimUppsala universitet,Institutionen för farmaci (författare)
  • Marshall, Derrick J.Lonza, Global Res & Dev, Bend, OR 97703 USA;Amgen Inc, Pivotal Drug Prod Technol, Cambridge, MA 02141 USA (författare)
  • Amidon, Gregory E.Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, Ann Arbor, MI 48103 USA (författare)
  • Bergström, Christel,1973-Uppsala universitet,Institutionen för farmaci(Swepub:uu)cjo29958 (författare)
  • Lonza, Global Res & Dev, Bend, OR 97703 USAInstitutionen för farmaci (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:AAPS Journal: SPRINGER22:21550-7416

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy